(S)-Ebvaciclib

• CAT Number: I017237
• CAS Number: 2185859-59-8
• Molecular Formula: C20H27F2N5O4S
• Molecular Weight: 471.52
• Purity: ≥95%
• Synonyms: 6-(difluoromethyl)-8-[(1S,2S)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one
• InChI: InChI=1S/C20H27F2N5O4S/c1-20(29)7-3-4-15(20)27-17-12(10-14(16(21)22)18(27)28)11-23-19(25-17)24-13-5-8-26(9-6-13)32(2,30)31/h10-11,13,15-16,29H,3-9H2,1-2H3,(H,23,24,25)/t15-,20-/m0/s1
• InChIKey: QIEKHLDZKRQLLN-YWZLYKJASA-N
• SMILES: CC1(CCCC1N2C3=NC(=NC=C3C=C(C2=O)C(F)F)NC4CCN(CC4)S(=O)(=O)C)O

(S)-Ebvaciclib(CAT: I017237) is a selective and orally active cyclin-dependent kinase (CDK) 4/6 inhibitor with potent antiproliferative activity. By blocking CDK4/6-mediated phosphorylation of the retinoblastoma (Rb) protein, it halts cell cycle progression from G1 to S phase, thereby suppressing tumor cell proliferation. (S)-Ebvaciclib demonstrates strong efficacy in preclinical cancer models, particularly against breast cancer and other solid tumors where dysregulated CDK4/6 signaling is a key driver of oncogenesis. With favorable pharmacokinetic properties, it serves as a valuable tool for cancer research and the development of targeted therapies.